Product and Trial Details

Lupin announced that results from its Phase 1a trial evaluating LNP8701, a novel SOS1 inhibitor, have been accepted for publication at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting, held from May 29-June 2, 2026, in Chicago, IL.

The abstract titled "A phase 1 study to evaluate safety, tolerability, and pharmacokinetics of LNP8701 (SOS1 inhibitor) in subjects with metastatic solid tumors" has been published in the Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology track on the ASCO website.

Drug Mechanism

LNP8701 is an orally administered, investigational SOS1 (Son of Sevenless1) inhibitor designed to block SOS1-mediated RAS activation, thereby limiting oncogenic signaling that promotes tumor growth.

Clinical Results

Results indicate that LNP8701 was well tolerated with desirable safety, pharmacokinetics profile and favorable anti-tumor activity. The preliminary efficacy findings demonstrate that:

  • Two patients completed LNP8701 monotherapy for 12 cycles (1 year)
  • One patient completed 14 cycles with stable disease
  • Current data suggest that LNP8701 is safe and well-tolerated across all tested dosing levels

Management Commentary

Vinita Gupta, CEO of Lupin, stated: "The findings from the ongoing Phase 1 study highlight the emerging potential of LNP8701 and signal progress in our pursuit of novel therapies for difficult-to-treat cancers. We are encouraged by this momentum and remain committed to transforming scientific discovery into meaningful patient outcomes."

Future Development Plans

Lupin will continue to study the efficacy of LNP8701 in its phase 1b trial in India and explore its potential to treat solid tumors both as a monotherapy and as part of a combination.

Technical Details

  • Abstract Number: e15162
  • Citation: J Clin Oncol 44, 2026 (suppl 16; abstr e15162)
  • DOI: 10.1200/JCO.2026.44.16_suppl.e15162
  • Clinical Trial Registration Number: CTRI/2024/08/072373
  • Abstract link: https://www.asco.org/abstracts-presentations/264586

Company Background

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. The company specializes in pharmaceutical products including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Lupin has 15 manufacturing sites and 7 research centers globally, with over 24,000 professionals. The company maintains subsidiaries including Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.